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The cellular oxygen sensing prolyl-4-hydroxylase domain proteins (PHDs) are essential 
regulators of the α-subunit of hypoxia-inducible transcription factors (HIFs) which are known 
to induce a variety of genes affecting cell survival, metabolism and angiogenesis. It was 
shown by the Institute of Cardiovascular Physiology, University Medical Center Göttingen, 
that stabilization of HIF-1α in cardiomyocyte-specific PHD2 knock out mice results in a 
tissue protective effect in acute myocardial infarction (MI) (Hölscher et al., 2011). Thus, 
pharmaceutical stabilization of HIF-1α with small molecule PHD inhibitors could be a 
suitable approach to induce cytoprotection in case of ischemia. Besides cardiomyocytes, 
fibroblasts are essentially involved in the organisation of the myocardium as well as in 
postischemic remodeling. In order to develop new cardio-protective therapeutic strategies, 
there is a strong need to further define fibroblast-specific functions in hypoxia and the role of 
HIF-1α in fibroblastic properties. Therefore, the aims of this thesis were (i) to evaluate the 
effect of a pharmaceutical PHD inhibition using the isoquinoline analog 2-(1-chloro-4-
hydroxyisoquinoline-3-carboxamido) acetate (ICA) for its applicability and protective 
properties in the heart, (ii) to analyze the role of PHD2 in cardiac fibroblasts via an inducible 
fibroblast-specific PHD2 knock out mouse, as well as (iii) to examine the morphological and 
functional responses of fibroblasts to hypoxia in vitro. I could show that L929 fibroblasts 
respond to hypoxia with striking morphological changes including an enlargement of cell area 
and volume, increased focal contact assembly and a dramatic reorganization of the actin 
cytoskeleton with prominent β-actin enriched circular stress fibers. These hypoxic adaptions 
are associated with enhanced cell spreading as well as reduction in migration properties. 
Furthermore, it could be shown that the maintenance of p-cofilin levels is dependent on HIF-
1α which subsequently affects the actin filament arrangement and may cause the observed 
increase in cell area and reduction in migration under hypoxic conditions. 
To study the role of HIF-1α in fibroblastic properties in vivo a tamoxifen-inducible fibroblast-
specific PHD2 knock out mouse was generated and Cre-mediated DNA recombination of 
Phd2 loxP sites could be detected, but lacks PHD2 knock out efficacy on mRNA and protein 
level.   
I could show that the PHD inhibitor ICA leads to a rapid and strong HIF-1α and HIF-2α 
accumulation in the heart and to the induction of HIF target genes which subsequently exert 
acute cardio-protective effects in MI. ICA treatment significantly reduced total infarct size 
after MI. This effect was seen not only after pre-conditional treatment, but also after post-





treatment of ischemic diseases with systemic PHD inhibitors as a useful tool for clinical 
approaches.  
Summing up, I could show that hypoxia and specifically HIF-1α greatly affects fibroblastic 
properties and functions and that a transient HIF-1α stabilization via small molecule PHD 
































Oxygen is essential for cell homeostasis. In the alveoli of the lungs the erythrocytes are 
enriched with oxygen, a process referred to as oxygenation of the hemoglobin. Via blood flow 
cells are supplied with oxygen to produce energy by ATP generation. If the oxygen demand 
of cells is higher than the availability hypoxia develops. An impaired oxygen delivery not 
only occurs in diseased states, but also under physiological conditions. Physiologically 
reduced oxygen concentrations ranging from 1% to 5% O2 are important for proper 
mammalian embryonic development (Chen et al., 1999; Okazaki and Maltepe, 2006). 
Hypoxia also occurs when ascending to higher altitude, where the low oxygen partial pressure 
can lead to high altitude illness in unacclimatized persons (Hackett and Roach, 2001). 
Physiologically induced hypoxia also develops during endurance sports when the oxygen 
demand of the muscles exceeds the oxygen delivery by the cardiovascular system leading to 
anaerobic energy metabolism. Besides physiological hypoxia, limited oxygen supply to 
tissues can occur in several disease conditions like cardiovascular or chronic lung diseases, 
stroke, cancer and anemia. Cellular responses to hypoxia are mediated by the transcription 
factors hypoxia-inducible factor (HIF), which regulate the transcription of several genes 
involved in adaption to cellular or systemic hypoxic conditions (Wenger, 2002, and references 
therein). These are genes which are involved in processes like erythropoiesis, angiogenesis 
and energy metabolism and thus enable survival in a low-oxygen environment (Semenza, 
2002). 
 
1.2 The Hypoxia inducible Factor (HIF) 
Hypoxia inducible factors act as the master regulators to mediate adaptional genetic responses 
of cells under hypoxic conditions. 
1.2.1 Structure and regulation of HIF 
HIF is a heterodimeric protein consisting of an oxygen dependend labile 120 kDa α-subunit 
and an oxygen-insensitive stable 91-94 kDa β-subunit. Both subunits belong to the PER-
ARNT-SIM (PAS) protein family of the basic helix-loop-helix (bHLH) transcription factors 
(Wang et al., 1995). The amino-terminal domain consists of the bHLH and PAS domains 





the HIFα and HIFβ subunits, respectively. The dimer specifically binds to hypoxia responsive 
elements (HREs) of target genes to induce gene expression (Jiang et al., 1996). 
In human and rodent cells three HIFα subunits HIF-1α, HIF-2α and HIF-3α exist. All three 
subunits are able to dimerize with the ubiquitously expressed HIF-1β subunit. Whereas HIF-
1α is ubiquitously expressed, HIF-2α and HIF-3α show more restricted tissue expression 
patterns with a higher HIF-2α expression in lung, brain and endothelial cells (Tian et al., 
1997; Ema et al., 1997; Chavez et al., 2006). HIF-3α was reported to be expressed in alveolar 
epithelial cells, kidney and vasculature (Hara et al., 2001; Li et al., 2006; Augstein et al., 
2011). HIFs play a fundamental role during embryogenic development as a knockout of HIF-
1α and HIF-2α leads to embryonic lethal phenotypes. HIF-1α is required for normal 
vascularization and cephalic mesenchymal cell survival and knock out animals show 
cardiovascular malformations and open neural tube defects (Iyer et al., 1998). HIF-2α knock 
out embryos die due to bradycardia and vascular disorganization (Tian et al., 1998; Peng et 
al., 2000). 
HIF-1α and HIF-2α share the most common similarities concerning structure, regulation and 
DNA binding (Tian et al., 1997). Both contain two transactivation domains, the N-terminal 
transactivation domain (N-TAD) and the C-terminal transactivation domain (C-TAD) (Pugh 
et al., 1997; O'Rourke et al., 1999) (Figure 1). The N-TAD contains the oxygen-dependent 
degradation (ODD) domain which is hydroxylated at the two proline residues Pro402 and 
Pro564 by prolyl-4-hydroxylase enzymes (PHDs) under normoxic conditions (Ivan et al., 
2001; Jaakola et al., 2001). The hydroxylated proline is recognized by the E3 ubiquitin ligase 
von Hippel-Lindau protein (pVHL), which leads to polyubiquitination and subsequent 
proteasomal degradation of HIF-1α (Maxwell et al., 1999). The protein levels of HIF-1α 
under normoxic conditions are tightly regulated with a short half-life of 5-8 min (Berra et al., 
2001).  
In addition to the modification of proline residues, HIF-1α and HIF-2α are hydroxylated by 
factor inhibiting HIF (FIH) at the asparaginyl residues Asn803 and Asn851, respectively. The 
asparagine hydroxylation interferes with the recruitment of the transcriptional coactivator 
CREB binding protein CBP/p300. The CPB/p300 cofactor is a histone acetyltransferase. 
Histone acetylation leads to increased transcriptional activity by ‘opening’ the genomic locus 
(Lando et al., 2002). Furthermore, the heat shock protein 90 (HSP90) can form a stable 
association with HIFα by interacting with its PAS B domain (Minet et al., 1999; Katschinski 





HIF-3α shows a high similarity to HIF-1α and HIF-2α regarding the bHLH and PAS domains, 
but lacks the C-TAD (Gu et al., 1998). A HIF-3α splice variant termed inhibitory PAS (IPAS) 
was identified in mice, which due to its lack in the transactivation domain, acts as negative 
regulator of the HIF-1/2 pathway (Makino et al., 2001 and 2002).  
 
1.2.2 HIF activation and target genes 
Hypoxia causes HIF-1α stabilization. The subsequent nuclear import of HIF-1α is facilitated 
by unmasking its C-terminal bipartite nuclear localization signal (NLS) via destabilization of 
the HIFα/HSP90 complex (Gradin et al., 1996; Kallio et al., 1998; Luo and Shibuya, 2001). 
Nuclear import is mediated by the interaction of the NLS with importins. Importins 4 and 7 
were shown to interact directly with HIF-1α (Chachami et al., 2009). After release from 
importins in the nucleus HIF-1α dimerizes with HIF-1β through intermolecular interactions of 
their bHLH and PAS domains. The C-TAD of HIF-1α is activated and the transcriptional 
coactivator CBP/p300 recruited (Gradin et al., 2002). The transcriptional active HIF-1 
complex recognizes HREs that contain the DNA consensus sequence RCGTG to induce the 
expression of HIF target genes (Semenza et al., 1996). To date more than 200 HIF target 
genes are known which are involved in adaptional physiological responses including 
angiogenesis, erythropoiesis and glycolysis. They include the vascular endothelial growth 
factor (VEGF), the most potent promoter for neoangiogenesis in hypoxic tissues (Liu et al., 
1995). It increases capillary density and thus leads to an improved tissue oxygenation (Ferrara 
Figure 1: Schematic drawing of the structure and regulation of HIF-1α. HIF-1α contains the basic helix-
loop-helix (bHLH) domain for DNA binding and PER-ARNT-SIM (PAS) domains for dimerization with HIF-
1β. The oxygen-dependent degradation domain (ODD) which is partially located within the N-terminal 
transactivation domain (N-TAD) is hydroxylated at the two proline residues Pro402 and Pro564 by proly-4-
hydroxylase enzymes (PHDs) in normoxia. Hydroxylated HIF-1α is recognized by the von Hippel-Lindau 
(pVHL) E3 ubiquitin ligase and is targeted for proteasomal degradation. The C-terminal transactivation domain 
(C-TAD) can be hydroxylated by factor inhibiting HIF (FIH) at Asn803. This hydroxylation interferes with the 





and Gerber, 2001). In addition to VEGF the production of erythropoietin (EPO) is also 
increased and stimulates erythropoiesis (Beck et al., 1993). Besides this, HIF-1 also 
upregulates a number of molecules like the inducible nitric oxide synthase (iNOS) and the 
heme oxygenase-1 (HO-1) which synthesize nitric oxide (NO) and carbon monoxide (CO) 
respectively, and thus modulate the vascular tone (Lee et al., 1997; Melillo et al., 1997). 
Under hypoxic conditions the limited oxygen supply causes a switch to anaerobic glycolysis 
to maintain cellular ATP production. To achieve this, several glycolytic enzymes like 
aldolase A, enolase 1, lactate dehydrogenase A, phosphofructokinase L, and phosphoglycerate 
kinase 1 and the glucose transporter 1 (GLUT-1) are upregulated by HIF-1 (Wenger, 2000, 
and references therein; Minchenko et al., 2002). These enzymes and transporters lead to an 
increased glucose uptake as well as an enhanced anaerobic ATP synthesis. The 
transmembrane carbonic anhydrase IX is induced by HIF-1 to regulate the pH by converting 
the arising protons and bicarbonate to carbon dioxide (Wykoff et al., 2000).  
 
1.3 Prolyl-4-hydoxylase domain enzymes 
Prolyl-4-hydoxylase domain enzymes (PHDs) are known to hydroxylate the HIFα subunit in 
an oxygen-, iron- and 2-oxoglutarate (2OG) dependent manner. This strict dependency on 
oxygen sets the PHDs up to function as cellular oxygen sensors. Three isoforms, PHD1, 
PHD2 and PHD3 are known. Although all three family members are able to hydroxylate 
HIFα, PHD2 appears to be the main oxygen sensor in normoxia (Berra et al., 2003).  
PHD1-3 are expressed ubiquitously with high expression levels of PHD1 in the testis and 
hormone responsive tissues (Lieb et al., 2002). PHD3 is abundant in the heart and skeletal 
muscle as well as in the placenta (Lieb et al., 2002). PHD2 is constitutively expressed in all 
tissues (Berra et al., 2003).  
The expression of PHD2 and PHD3 is hypoxic inducible as both contain HREs within their 
promoter regions. This regulation serves as a negative feedback loop and enables the rapid 
degradation of HIFα during reoxygenation (Metzen et al., 2003; Schofield and Ratcliffe, 
2004). The expression of PHD1 is not hypoxia inducible; however PHD1 can be induced in 
human breast cancer cells by estrogen (Seth et al., 2002).  
The three PHDs exhibit different cell localization patterns. Whereas PHD1 was shown to be 
exclusively present in the nucleus, PHD2 is mainly localized in the cytoplasm, and PHD3 can 
be found in both cell compartments with cytoplasmic predominance (Metzen et al., 2003; 





1.3.1 PHD activity 
PHDs hydroxylate two critical prolines within a strongly conserved LXXLAP motif within 
the ODD of HIF-1α, -2α or -3α subunits (Huang et al., 2002). Whereas PHD1 and PHD2 
recognize the two critical proline residues 402 and 564 in human HIF-1α, PHD3 hydroxylates 
with a higher preference proline 564 (Epstein et al., 2001; Hirsilä et al., 2003).  
PHDs fulfill the requirements to function as oxygen sensors in eukaryotic cells, because their 
Km values are 230 - 250 µM and thus slightly above the concentration of dissolved O2 in air 
(Hirsilä et al., 2003). This leads to highly sensitive changes in PHD activity in response to 
decreases in tissue oxygen availability. 
At the catalytic site of PHD enzymes iron is non-covalently ligated by two histidines and one 
aspartic residue. These protein ligands form a ‘facial triad’ that occupies three of six possible 
iron coordination sites (Schofield and Ratcliffe, 2004). 2OG is ligated to Fe
2+
 through its 1-
caboxylate and 2-oxo goups (Figure 2) at the two further coordination sites. The remaining 
coordination site is occupied by one labile water molecule which is readily displaced by the 
HIFα substrate. This displacement leads to oxygen binding and activation of the enzyme. The 
uncoordinated oxygen of the bound dioxygen attacks the ketone carbonyl group of the 2OG 
forming a bicyclic Fe(IV)-peroxyhemiketal complex. This complex undergoes 
decarboxylation concomitantly with the formation of an oxo-ferryl (Fe(IV)=O) intermediate 
and the release of CO2. The highly reactive intermediate attacks the HIFα proline residues to 
withdraw a hydrogen atom and then introduces the hydroxyl radical. After release of the 
hydroxylated HIFα ODD succinate is also separated from the complex and the free iron 
coordination sites are again occupied by water molecules (Schofield and Ratcliffe, 2004; 
Smirnova et al., 2012). 
 
Figure 2: Outline of the catalytic 




complex able to bind the substrate 
HIFα (HR; blue) by the release of 
water. They transfer one of the 
oxygen atoms (purple) onto the HIFα 
proline residues (HR to HOR) and 
the second oxygen atom reacts with 
2-oxoglutarate via oxidative 
decarboxylation to give succinate 
(green) and carbon dioxide (taken 





The PHDs might require in addition ascorbate for their full catalytic activity as an alternative 
oxygen acceptor in uncoupled decarboxylation cycles as it has been described for collagen 
PHDs (Myllylä et al., 1984). However, it has been reported that ascorbate might be 
dispensable for HIFα hydroxylation and glutathione could substitute for ascorbate in vivo 
(Nytko et al., 2011).  
 
1.3.2 PHD in vivo functions 
To gain deeper insight into in vivo functions of the PHDs several knock out mice were 
generated and characterized. Ubiquitous PHD2 knock out
 
mice are not viable as PHD2 knock 
out embryos die between E12.5 and E14.5 because of early cardiac and placenta defects. 
These mice present severe heart defects including thinner ventricular compact layer, poorly 
developed trabecula, open interventricular septum and enlarged atria. The placentas of these 
animals show a reduced vascularization in the irregularly formed labyrinth, an abnormal 
distribution of giant cells and widespread penetration of the labyrinth by spongiotrophoblasts 
(Takeda et al., 2006; Minamishima et al., 2008). In contrast to this, PHD1 knock out mice do 
not present any obvious phenotype under basal conditions (Aragonés et al., 2008). However, 
the skeletal muscles of PHD1 knock out animals are protected against lethal ischemia due to 
metabolic adaption towards oxygen conservation. PHD3 knock out mice are viable, but PHD3 
was reported to regulate neuronal apoptosis as well as adrenal medulla morphology and 
sympathoadrenal development. Thus, the sympathoadrenal system was described to be 
dysfunctional in PHD3 knock out mice with reduced innervation of target organs and 
dysregulated responses, including reduced catecholamine secretion and reduced systemic 
blood pressure (Bishop et al., 2008). 
 
1.4 PHD inhibitors 
Inhibition of PHD enzymes might partly induce a protective effect by stabilizing HIFα in 
normoxia. Several PHD inhibitors have been described for in vitro and in vivo applications 
and have been tested in clinical and pre-clinical trials for their tissue protection potential 
(Katschinski, 2009). Inhibition of the enzymatic activity of PHDs can be achieved by the 
usage of competitive substrate analogs, iron chelators like desferrioxamine (DFO), or iron 
replacement by transition metal ions like cobalt, nickel and manganese (Epstein et al., 2001; 
Schofield and Ratcliffe, 2004). Additionally, it was found that the endogenous 2-oxoacids 





oxygenases (Tuderman et al., 1977). 2OG-substrate analogs such as dihydroxybenzoate 
(DHB) and dimethyloxalylglycine (DMOG) bind in a similar fashion like 2OG to the PHDs. 
These 2OG-substrate analogs also displace the water molecule, however due to their structure 
they cannot be oxidized which will result in uncoupled reactions (Smirnova et al., 2012). 
Non-selective oxoglutarate analogs such as N-oxalyl-glycine and DMOG were used in 
different applications in vitro (Jaakkola et al., 2001; Epstein et al., 2001), but these agents are 
likely not suitable enough for the clinical use because they inhibit many 2-OG-dependent 
dioxygenases besides PHD1-3 (Ivan et al., 2002). 
As PHDs exhibit isoform-specific functions in vivo, it is important to use or develop PHD 
isoform-specific inhibitors to induce distinct HIFα actions and to reduce unwanted side 
effects. Several structurally diverse small molecule inhibitors were developed and tested 
regarding their PHD enzyme inhibiting properties. Isoquinoline based inhibitors and 4-
Hydroxy-2-oxo-1,2-dihydroquinoline glycinamide analogs (4HQs) seem to be more selective 
for PHDs than the non-selective oxoglutarate analogs N-oxalyl-glycine and DMOG. While 
DMOG inhibits besides to PHDs also FIH, the isoquinoline analogs and 4HQs inhibition 
properties are almost restricted to PHDs. PHD isoform specificity could also be improved by 
varying side chains. Furthermore, isoquinoline analogs and 4HQs were reported to be more 
potent in stabilizing HIFα than the non-selective PHD inhibitors (Stubbs et al., 2009; 
Chowdhury et al., 2013). Therefore, these PHD inhibitors seem to be more suitable for 
clinical use. These substances were successfully used in in vivo experiments to stimulate 
erythropoiesis (Safran et al., 2006; Hsieh et al., 2007) as well as to exert tissue protective 
effects in ischemic diseases in the kidney, heart and brain (Philipp et al., 2006; Baranova et 
al., 2007; Rosenberger et al., 2008; Bao et al., 2010).  
 
1.5 Ischemic heart disease 
Ischemic heart disease is one of the leading causes of mortality worldwide (Mathers and 
Loncar, 2006). It is in most cases age dependent, with a prevalence of 2.3% in persons 
younger than 50 years versus 15.1% in those with an age over 60 (Gösswald et al., 2013). 
Ischemia occurs in the heart e.g. when an atherosclerotic plaque in the wall of a major 
coronary artery blocks the blood perfusion. This leads to inadequate oxygen and nutrient 
delivery to the heart tissue. This shortage of O2 and nutrient supply can cause cell death and 
necrosis of the ischemic tissue after prolonged arterial occlusion and subsequently myocardial 





observed in biopsy specimens obtained from ischemic or infarcted human myocardium (Lee 
et al., 2000). In addition to this, the tissue undergoes after the acute infarction complex 
remodeling processes including changes in cell metabolism, matrix production by fibroblasts 
and myocyte replication (Williams and Benjamin, 2000). This myocardial remodeling after 
ischemia can also lead to tissue stiffness, dilatation and ventricular dysfunction, disability and 
death (Pfeffer et al., 1990). 
 
1.6 Animal models to mimic myocardial infarction  
Transient myocardial ischemia is due to an imbalance between coronary perfusion as well as 
oxygen and nutrient demand resulting in a state of myocardial impairment. Tissue viability 
can be preserved by reperfusion within 20 minutes. Severe and prolonged ischemia however 
leads to irreversible injury and subsequent necrosis (Braunwald and Kloner, 1985). As a 
murine in vivo model, the surgical ligation of the left anterior descending artery (LAD) is well 
accepted to resemble MI (Patten et al., 1998).  The LAD appears to be the major supplier of 
blood and nutrients to the left ventricle, whereby it courses either as a single major vessel to 
the apex or it bifurcates into two major vessels (Michael et al., 1995). After ligation of the 
LAD no further blood flow is permitted into the apex of the left ventricle resulting in an 
ischemic area, while the surrounding myocardial tissue is almost not affected. The size of the 
ischemic myocardium as well as viable areas within the infarction can be determined by using 
Evan’s blue/2,3,5-triphenyltetrazolium chloride (TTC) staining (Bohl et al., 2009). 
Furthermore, the heart function and cardiac remodeling after MI can be evaluated in living 
animals by echocardiography.  
 
1.7 The cardio protective role of HIF-1α in the heart 
It was shown that hearts exposed to short episodes of ischemia and reperfusion (i.e. 5 min) 
were protected against injury caused by a subsequent prolonged episode of ischemia-
reperfusion (30 min). This phenomenon is also known as ischemic preconditioning (IPC) 
(Murry et al., 1986). The protection exhibits two phases, the first directly after reperfusion 
which lasts for several hours and the second which starts 24 h after the stimulus and lasts for 
several days (Murry et al., 1986; Kuzuya et al., 1993; Marber et al., 1993). In contrast, hearts 
directly subjected to prolonged ischemia-reperfusion without IPC showed dramatically 
increased infarct sizes (Liu et al., 1991). In the early phase it is postulated that IPC induces 





membrane proteins hydrolyze ATP to adenosine an obligatory mediator of acute 
cardioprotection (Liu et al., 1991; Semenza, 2014). In addition to this, it was shown that HIF-
1 is first induced in the infarct surrounding tissue, shortly thereafter also in the non-infarcted 
myocardium (Jürgensen et al., 2004). As HIF-1 induces hundreds adaptive genes upon 
ischemia it probably plays an important role in IPC. 
Cardioprotective effects of the HIF pathway have also been reported in the setting of acute 
MI. Genetically modified mouse models in which HIF-1α is stabilized in cardiomyocytes 
show improved cardiac function and reduced infarct size after MI (Kido et al., 2005; Hölscher 
et al., 2011). Beneficial effects after MI were also reported for the injection of small hairpin 
RNA targeting PHD2 (Huang et al., 2008). And also the treatment of mice with PHD 
inhibitors like cobalt chloride, DFO, DMOG and GSK360 is protective in the case of MI (Xi 
et al., 2004; Dendorfer et al., 2005; Eckle et al., 2008; Bao et al., 2010). The underlying 
mechanisms are not understood in detail, however increased capillary area, metabolic 
reprogramming towards glucose consumption and altered calcium handling have been 
discussed to be involved in HIF-dependent cardioprotection. 
On the other hand, long-term activation of HIF-1 and its associated pathways may actively 
contribute to heart failure (Hölscher et al., 2012). 
 
1.8 The role of fibroblasts in the heart 
Besides cardiomyocytes, which occupy approximately 75% of the normal myocardial tissue 
volume and 30-40% of cell numbers, the majority of the remaining cells are predominantly 
fibroblasts (Vliegen et al., 1991; Camelliti et al., 2005). Fibroblasts are defined as cells of 
mesenchymal origin that produce a variety of extracellular matrix (ECM) components, 
including multiple collagens, as well as fibronectin (Souders et al., 2009). They contribute to 
cardiac development, cell signaling and electro-mechanical properties of the myocardium 
(Camelliti et al., 2005). The content of fibroblasts in the heart increases during normal 
development and aging (Anversa et al., 1986). In diseased states like myocardial ischemia, 
fibroblasts play an important role in cardiac tissue remodeling. This is due to their ability to 
secrete and breakdown the ECM. They infiltrate the damaged tissue within hours after 
myocardial infarction with a maximum density after one week (Camelliti et al., 2005).  
Fibroblasts can differentiate into myofibroblasts that are specialized cells which possess a 
more contractile and synthetic phenotype than fibroblasts. Due to the expression of contractile 





generate force which is applied to the surrounding extracellular matrix (Tomasek et al., 2002; 
Gabbiani et al., 2003). Myofibroblasts deposit increasing amounts of ECM in order to 
preserve tissue integrity resulting in myocardial scar formation (Cleutjens et al., 1995). 
However, excessive ECM production may also cause impaired cellular communication and 
electrical propagation in the heart (Kohl et al., 2005). Besides the role of fibroblasts in ECM 
deposition, they also express matrix metalloproteinases (MMPs) and humoral factors (e.g. 
TGF-β, angiotensin II and TNF-α) resulting in inflammatory cell infiltration and cytokine 
production that further enhances fibroblast infiltration, proliferation and differentiation (Tao 
et al., 2004).  
 
1.9 The role of the actin cytoskeleton in fibroblastic properties   
Infiltration of fibroblasts into an ischemic tissue like the infarcted heart is a complex process. 
The most important step for the migration of fibroblasts is the rearrangement of the actin 
cytoskeleton, yet not much is known about hypoxia-induced effects on the cytoskeleton based 
fibroblast architecture and function.  
The actin cytoskeleton mediates a variety of biological functions like cell morphology, 
polarity, motility, cell division and intracellular transport. Vertebrates express six actin 
isoforms, including α-skeletal, α-cardiac, α- and γ-smooth muscle, and the two cytoplasmic β- 
and γ-actins. They differ by only a few amino acids (Vandekerckhove and Weber, 1978; 
Herman, 1993). 
Actin exists as globular G-actin monomers which can assemble into long filamentous F-actin 
polymers that are polar helical structures. G-actin contains a Mg
2+
-ion complexed with either 
ATP or ADP. The assembly into F-actin is accompanied with the hydrolysis of ATP to ADP 
and Pi. Monomer assembly is the dominant reaction at the fast growing (i.e. barbed) ends of 
actin filaments, whereas filament disassembly prevails at the slow growing (i.e. pointed) end 
(Wegner, 1976; Wegner and Isenberg 1983). The actin microfilaments, which form a three-
dimensional cytoskeletal network throughout the cell, are shaping the cell morphology via 
continuous remodeling (Winder, 2003). Besides this, the continuous turnover of the actin 
cytoskeleton is essential for the migration of fibroblasts which goes along with phases of 
protrusion and contraction as a cyclical process. Every step of this cycle critically depends on 
the timely assembly, disassembly, and reorganization of actin filaments as well as contractile 
actomyosin structures (Horwitz and Parsons, 1999). These actomyosin structures are termed 





crosslinked by α-actinin and myosin (Tojkander et al., 2012). They are often anchored to 
focal adhesions to connect the ECM to the cytoskeleton and can be divided in dorsal and 
ventral stress fibers, as well as in transverse arcs with distinct functions. Whereas highly 
motile cells contain few, thin and dynamic stress fibers, thick and relative stable actin stress 
fibers are prominent in stationary cells as they may inhibit cell migration (Burridge, 1981; 
Pellegrin and Mellor, 2007).  
The mechanisms of actin dynamics are mainly controlled by members of the Rho family of 
small GTPases which includes over 20 different members (Heasman and Ridley, 2008). The 
RhoGTPases RhoA, Rac and Cdc42 are the best characterized family members (Hall, 1998). 
RhoA plays an important role in the assembly of stress fibers and is therefore required for 
generating contractile forces (Ridley and Hall, 1992). Besides this, Rac plays a fundamental 
role in actin polymerization leadig to lamellipodium and membrane ruffle formation (Ridley 
et al., 1992). Cdc42 has been shown to act as a key regulator for cell polarity and filopodium 
formation (Nobes and Hall, 1995, 1999). These processes including actin polymerization, 
stress fiber- and focal adhesion formation are mainly controlled by Rho through effectors such 
as the Rho associated kinase ROCK. ROCK regulates the actin cytoskeleton turnover by 
modulating the activity of actin-binding proteins (Jaffe and Hall, 2005). One actin-binding 
and severing protein is cofilin. Its activity was shown to be regulated by RhoA/ROCK/LIM-
domain kinase-dependent phosphorylation to regulate F-actin formation (Ohashi et al., 2000). 
Furthermore, cofilin is also important for the maintenance of a polarized cytoskeleton that is 
indispensable for directional cell migration (Dawe et al., 2003). 
 
1.10 Aim of this study  
Since oxygen-dependent gene expression is involved in adaptive cellular mechanisms and 
angiogenesis, manipulation of the HIF pathway via interfering with PHD activity is an 
attractive strategy for tissue protection (Katschinski, 2009). In line, cardiomyocyte-specific 
HIF-1α stabilization has been reported to be protective against acute ischemia (Kido et al., 
2005; Hyvärinen et al., 2010; Moslehi et al., 2010; Hölscher et al., 2011) and PHD enzymes 
have been identified as drugable targets to affect hypoxia-induced signaling in the heart. One 
aim of this thesis was to analyze the PHD inhibitor ICA with regard to its cardioprotective 
effects and to add to the understanding of the available time frame for the application of PHD 





As cardiac fibroblasts play an important role in tissue remodeling after MI another objective 
of this work was to investigate the consequences of hypoxia and HIFα-stabilization on 
fibroblast function. Overall this thesis should add to our understanding of cardio-protective 


























2. Original Publications 
This chapter contains the following original publications which have been published before 
the submission date of this thesis. 
 
Hypoxia Modulates Fibroblastic Architecture, Adhesion and Migration: A Role for 
HIF-1α in Cofilin Regulation and Cytoplasmic Actin Distribution 
Melanie Vogler*, Sabine Vogel*, Sabine Krull, Katja Farhat, Pia Leisering, Susanne Lutz, 
Christina M. Wuertz, Dörthe M. Katschinski, Anke Zieseniss  
*both authors contributed equally 
PLoS ONE 8.7 (2013): e69128 
 
Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects 
the heart from an ischemic insult 
Melanie Vogler*, Anke Zieseniss*, Amke R. Hesse, Elif Levent, Malte Tiburcy, Eva Heinze, 
Nicolai Burzlaff, Gunnar Schley, Kai Uwe Eckardt, Carsten Willam, Dörthe M. Katschinski  
*both authors contributed equally 


















2.1 Hypoxia Modulates Fibroblastic Architecture, Adhesion and Migration: A 
Role for HIF-1α in Cofilin Regulation and Cytoplasmic Actin Distribution 
Fibroblasts play a fundamental role during embryonic development, wound healing and tissue 
remodeling. These processes are often associated with reduced oxygen supply leading to a 
hypoxic environment of the cells (Chen et al., 1999; Tandara and Mustoe, 2004). Because not 
much is known about the effect of hypoxia on fibroblastic properties, I analyzed and 
described its effect on cell architecture and function of L929 fibroblasts in the following 
publication. The cell area and volume, spreading and migration properties and also the 
composition of the actin cytoskeleton were analyzed and compared between cells cultivated 
under hypoxic (1% O2) and normoxic (20% O2) conditions. I observed striking morphological 
changes in hypoxia including an increase in cell area, enhanced cell spreading, and a changed 
focal contact assembly as well as a reduced migration and changed actin isoform distribution 
in hypoxia. As cells respond to hypoxia by the stabilization of HIF-1α, I established HIF-1α 
knock down clones to examine its effect in the observed fibroblastic properties. In this 
publication I show an important role for HIF-1α in the cytoskeleton-related architecture and 
functional changes. 
 
2.1.1 Declaration of my contribution 
The experiments were conceived and designed by Prof. Dr. Dörthe M. Katschinski, Prof Dr. 
rer. nat. Susanne Lutz and Dr. rer. nat. Anke Zieseniss. The experimental part was mainly 
performed by me including data analysis (cell culture, fluorescence staining for the 
cytoplasmic actin isoforms and confocal microscopy, cell area analysis, flow cytometry 
analysis, single cell migration, scratch assay, protein extraction and immunoblot analysis for 
HIF-1α, β-tubulin, vinculin and integrin-β1) kindly supported by Dr. rer. nat. Sabine Vogel.  
The draft of the manuscript was written by Prof. Dr. Dörthe M. Katschinski and Dr. rer. nat. 
Anke Zieseniss. I wrote parts of the Material and Methods sections and proposed 
modifications for the publication. 











































































2.2 Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes 
protects the heart from an ischemic insult 
In ischemic tissues the stabilization of HIF-1α and the following transcription of hundreds of 
HIF target genes may exhibit tissue protective effects (Wenger, 2002, and references therein). 
Inhibition of PHD results in normoxic stabilization of HIF-1α and has been shown to exert 
cardio-protective effects in genetically modified mouse models (Hölscher et al., 2011) Thus, 
there is a strong need to develop selective small molecule PHD inhibitors as a new therapeutic 
option for myocardial tissue protection during ischemia. Therefore, we analyzed in this study 
the isoquinoline analog 2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido) acetate (ICA), a 
specific PHD inhibitor for its applicability and protective properties in the heart. ICA was 
tested for protective effects in acute MI induced by LAD ligation via pre- or post-conditional 
application. In the following publication I describe that ICA treatment leads to a rapid and 
strong HIF-1α and HIF-2α accumulation in heart muscle cells in vitro and in vivo and also to 
the induction of the known HIF target genes HO-1 and PHD3. It could be shown that ICA 
exerts acute cardio-protective effects in MI by a significantly reduced total infarct size. This 
effect was seen not only by pre-conditional treatment, but also after post-conditional 
application of ICA. This indicates that there is a therapeutic time window for the treatment 
with PHD inhibitors which could also be useful for acute clinical approaches. 
 
2.2.1 Declaration of my contribution 
The experiments were conceived and designed by Prof. Dr. Dörthe M. Katschinski and Dr. 
rer. nat. Anke Zieseniss. The animal experimentation was mainly performed by me including 
myocardial infarction, injection of ICA, echocardiography, collection of organs and blood as 
well as the corresponding analysis. Heart perfusion and Evan‘s blue/TTC staining was 
performed in collaboration with Dr. rer. nat. Anke Zieseniss who did the analysis of the total 
infarct size. The draft of the manuscript was mainly written by Prof. Dr. Dörthe M. 
Katschinski and Dr. rer. nat. Anke Zieseniss. I wrote parts of the Material and Methods 





























































3. Unpublished data 
In this chapter I describe unpublished data regarding the establishment of an inducible, 
fibroblast-specific PHD2 conditional knock out mouse model using the Cre-loxP system. 
 
3.1 Establishment of fibroblast-specific PHD2 knock out mice 
3.1.1 Abstract 
Since oxygen-dependent gene expression is involved in several adaptive mechanisms at the 
cellular and systemic level, manipulation of the HIF pathway by interfering with PHD activity 
is an attractive strategy for tissue protection (Katschinski, 2009). In line, cardiomyocyte 
specific HIF-1α stabilization has been reported to be protective in acute ischemia (Kido et al., 
2005; Hölscher et al., 2011). Besides cardiomyocytes, which account for 30-40% of cardiac 
cells, the majority of the remaining cells are fibroblasts (Vliegen et al., 1991; Souders et al., 
2009). They fulfill several important functions during heart development and in the normal 
cardiac homeostasis as well as in tissue remodeling involving fibrosis after myocardial 
infarction (Camelliti et al., 2005). Given the important role of fibroblasts in the healthy and 
diseased heart, it is important to take fibroblast function into account when considering the 
HIF pathway for treatment strategies. Thus, I set out to generate an inducible, fibroblast-
specific PHD2 knock out mouse. For this purpose, Phd2
flox/flox
 mice were crossed with mice 
which express an inducible Cre-recombinase under the control of the Col1α2 promoter and 
treated with different tamoxifen (TAM) administration protocols. The PHD2 knock out 
efficacy was analyzed on genomic DNA (gDNA), messenger RNA (mRNA), and protein 
level in tissue specimens or isolated primary fibroblasts. Via all administration routes I could 
observe DNA recombination, however hardly any PHD2 knock out was detected on mRNA 
and protein level. This reveals an insufficient recombination activity which may be caused by 
a low promotor activity and subsequently incomplete activation of the Cre-recombinase.  
 
3.1.2 Introduction 
When the oxygen delivery is impaired cells respond to hypoxia by stabilisation of HIFα, 
which is part of the heterodimeric transcription factor complex that regulates the transcription 
of genes affecting several adaptive processes, like angiogenesis, cellular metabolism and cell 
survival (Semenza, 2002). In normoxia PHDs hydroxylate HIFα and thus mark it for to 
ubiqitination and proteasomal degradation (Maxwell et al., 1999). Three isoforms, i.e. PHD1, 




PHD2 and PHD3 exist, which have the ability to hydroxylate the α-subunit of HIF. Among 
those PHD2 can be regarded as the main oxygen sensor in normoxia (Appelhoff et al., 2004).  
Since oxygen-dependent gene expression is involved in several adaptive mechanisms, 
manipulation of the HIF pathway by interfering with PHD activity is an attractive strategy for 
tissue protection (Katschinski, 2009). It was shown that stabilization of HIF-1α in 
cardiomyocyte-specific PHD2 knock out and HIF-1α transgenic mice can exert tissue 
protective effects in acute myocardial infarction (Kido et al., 2005; Hölscher et al., 2011). In 
addition, protective effects were also observed by pharmaceutical inhibition of PHDs and 
subsequent HIF-1α stabilization (Eckle et al., 2008; Bao et al., 2010; Vogler et al., 2015).  
Besides cardiomyocytes, which account for 30-40% of heart cells, the majority of the 
remaining cells are fibroblasts (Vliegen et al., 1991; Souders et al., 2009). They fulfill 
essential functions in cardiac development, cell signaling and electro-mechanical properties of 
the myocardium. They are also the main source of ECM proteins and are thus postulated to be 
important for the structural integrity of the heart and for the myocardial remodeling after 
infarction (Cleutjens et al., 1995; Camelliti et al., 2005).  
The fibroblast population of the heart is fundamental for the performance of the normal and 
the diseased heart. When considering systemic PHD2 inhibition as therapeutic approach in 
case of myocardial ischemia it is important to understand the effects not only in 
cardiomyocytes, but also in fibroblasts. However, the contribution of PHD2 and the HIF 
pathway to cardiac fibroblast function in the ischemic heart is not understood. Thus, I set out 
to generate an inducible, fibroblast-specific PHD2 knock out mouse model by intercrossing 
Tg(Col1α2-cre/ERT) deleter mice with Phd2
flox/flox
 mice. The deleter mice express a fusion 
product involving the Cre-recombinase-domain and a mutated estrogen-receptor ligand-
binding domain (ERT) under the control of a fibroblast-specific regulatory sequence from the 
proα2(I)collagen gene (Bou-Gharios et al., 1996). The Cre-recombinase is derived from the 
P1 bacteriophage and catalyzes the site specific recombination between two specific DNA 
recognition sites (LoxP-sites). These are palindromic sequences that were cloned into the 
PHD2 gene (Phd2
flox/flox
) (Hölscher et al., 2011). The Cre-recombinase can be activated by the 
binding of 4-OHT, the active metabolite of TAM. This activation permits access of the Cre-
recombinase to the nucleus and subsequent excision of the DNA sequence flanked by the 
LoxP sequences. Several TAM administration protocols were described for the activation of 
the Cre-recombinase in different mouse models including animals that express the Cre-
recombinase under the control of the Col1α2 promoter (Zheng et al., 2002; Hayashi and 
McMahon, 2002; Kiermayer et al., 2007; Denton et al., 2009). 




In this study I evaluated the PHD2 knock out efficacy in fibroblasts in vivo and in vitro using 
different TAM administration protocols and summarized their effects on gDNA, mRNA, and 
protein level. 
 
3.1.3 Materials and Methods 
Most chemicals and materials were obtained from Sigma-Aldrich, Hamburg, Germany or Carl 
Roth GmbH & Co. KG, Karlsruhe, Germany, if not indicated differently in the text. 
 
Mice 
Inducible, fibroblast-specific PHD2 knock out mice were generated by an intercross between 
Tg(Col1α2-cre/ERT) deleter mice (B6.Cg-Tg(Col1α2-cre/ERT)7Cpd/J, Stock No. 016237, 
Jackson Laboratories, Bar Harbor, Maine, USA) with Phd2
flox/flox
 mice. The Phd2
flox/flox
 mice 
were kindly provided by Prof. Dr. Breier and Dr. Wielockx, University Dresden, Germany. A 
detailed description of the Phd2
flox/flox
 mice was reported elsewhere (Hölscher et al., 2011). In 
brief these mice carry two LoxP-sites flanking exons 2 and 3 of the PHD2 gene which encode 
for almost the entire catalytic domain of Phd2. The Tg(Col1α2-cre/ERT) deleter mice express 
the Cre-recombinase fused to a ERT ligand binding domain under the control of a fibroblast-
specific regulatory sequence from the proα2(I)collagen gene (Bou-Gharios et al., 1996). 
Under basal conditions the inactive Cre-recombinase is located in the cytoplasm and becomes 
activated after binding of 4-OHT to the ERT leading to subsequent nuclear import and 
excision of the LoxP-flanked sequence. This leads to a frameshift mutation from exon 1 to 4 
of the PHD2 gene and to a translational stop. All mice used in this report were born in a 
normal mendelian ratio. All protocols regarding animal experimentation were conducted 
according to the German animal protection laws and approved by the responsible 
governmental authority (Niedersächsisches Landesamt für Verbraucherschutz und 
Lebensmittelsicherheit in Oldenburg; animal experimentation number 33.9-42502-04-
12/0833).  
 
Induction with TAM or 4-OHT 
10 mg TAM (T5648) and 5 mg 4-OHT (H6278, H7904) were dissolved in 500 µl 100% 
ethanol and vortexed (Vortex Genie 2TM; Schütt Labortechnik GmbH, Göttingen, Germany). 
9.5 ml conventional sunflower oil were added to gain final concentrations of 10 mg/ml TAM 




and 5 mg/ml 4-OHT. Solutions were incubated for 1 h at RT under constant agitation. The 
suspensions were sonicated at 10%-60% power, cycle 9 (Sonopuls SH 70 G, BANDELIN 
electronic GmbH & Co. KG, Berlin, Germany) for 15-30 min, the vials were briefly vortexed 
every 5-10 min until the solution appeared clear. If necessary, the 4-OHT suspensions were 
incubated up to 1 h at 65°C to dissolve all the 4-OHT. The solutions were stored in light 
protected containers. TAM stocks were kept at -20°C, whereas 4-OHT was used immediately.  
Experiments were performed with male and female mice at different ages from 7 days up to 
8 weeks old as indicated in the text, as well as with pregnant mice at day 12 post-conception 
(PC). Activation of the Cre-recombinase was contemplated using different TAM 
administration protocols. Animals received either TAM containing chow of a soy free food 
base (TD.55125 and T.2016.12, Harlan Laboratories Inc, Rossdorf, Germany) for up to 7 
weeks. In different attempts TAM was injected intraperitoneally (i.p.) (40 mg/kg, 200 mg/kg 
TAM, 50 mg/kg 4-OHT) using a 26-gauge needle with a 1 ml syringe (B. Braun, Melsungen 
AG, Melsungen, Germany). Injections were performed either at single time points (in 
pregnant mice) or serially. For serial injections mice were treated either weekly for three 
consecutive weeks or daily for up to 10 consecutive days. Tissue harvest and isolation of 
primary fibroblasts were carried out 4 weeks after the last feeding with tamoxifen containing 
chow or injection of TAM.  
 
Echocardiography 
Non-invasive evaluation of the cardiovascular function was performed by echocardiography. 
Mice were anaesthetized with 2% isoflurane (Forene
®
, AbbVie Deutschland GmbH & Co. 
KG, Ludwigshafen, Germany), depilated and fixed on a heating pad with ECG leads. 
Echocardiography was performed under anesthesia with 1% isoflurane. Two-dimensional 
images and M-mode tracings were recorded from the parasternal long axis view at 
midpapillary level (Vevo 2100TM, MS400; Visual Sonics, Toronto, Ontario, Canada). The 
heart rate, left ventricular enddiastolic diameter (LVEDD) and ensystolic diameter (LVESD) 
were determined. Fractional area shortening (FAS) of the left ventricle was defined as the 
LVEDD – LVESD divided by the LVEDD. The FAS was used as marker for cardiac function.  
 
Isolation and cultivation of primary fibroblasts 
To determine the knock efficacy of PHD2 in primary murine fibroblasts in different tissues, 
fibroblasts were isolated from tail, skin, kidney and the heart. 




Tails were removed from the mice using sterile scissors and incubated for 60 min on ice in 
20 ml DMEM (PAN-Biotech GmbH, Aidenbach, Germany) supplemented with 10% FCS 
(PAN-Biotech GmbH), 1% MEM-NEAA (PAN-Biotech GmbH) and 1% penicillin/ 
streptomycin (P/S) (PAN-Biotech GmbH). After washing the tails in PBS containing 2% P/S, 
they were dipped briefly in 70% ethanol and minced up using sterile scissors. Tissue was 
digested with 400 U/ml collagenase type II (#C2-22; Biochrom AG, Berlin, Germany) added 
to the media and incubated while agitating at 37°C overnight. Cells were passed through a 
70 µm nylon cell strainer (#22363548; Thermo Fisher Scientific Inc., Schwerte, Germany), 
centrifuged for 5 min at 1000 rpm and seeded in cell culture dishes. The medium was changed 
after 2 h.  
Skin was shaved and disinfected with 70% ethanol. The tissue was cut into 4 mm
2
 squares 
using a sharp scalpel and placed into a sterile cell culture dish covered by a sterile cover slip. 
Medium (DMEM, 10% FCS, 1% MEM-NEAA, 1% P/S) was added and changed every 
3 days until the skin fibroblasts, which migrated out of the tissue became confluent.  
Hearts and kidneys were harvested and washed in sterile PBS (137 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, 1.8 mM KH2PO4). The tissues were minced and digested at 37°C for 
10 min while agitating in digestion buffer containing 137 mM NaCl, 5.4 mM KCl, 0.25 mM 
Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1.0 mM MgSO4, 4.2 mM NaHCO3, 0.1% 
trypsin and 100 U/ml collagenase type IV (#C4-22; Biochrom AG). After precipitation of the 
cells for 1 min the first supernatant was discarded. The digestion-precipitation steps were 
repeated 4-5 times until the tissues were dissolved completely while supernatants were 
collected and spun down for 5 min at 1000 rpm at 4°C. Kidney fibroblasts were resuspended 
in DMEM, 10% FCS, 1% P/S, whereas DMEM/F-12, GlutaMAX™ (#31331-028 Life 
Technologies GmbH, Darmstadt, Germany) supplemented with 10% FCS, 1% P/S and 
100 µM ascorbic acid was used for cardiac fibroblasts. Cells were plated and the medium was 
changed after 2 h.  
The isolated fibroblasts were cultivated under cell culture conditions at 37°C, 5% CO2, 
20% O2 (Binder GmbH, Tuttlingen, Germany). 
 
In vitro tamoxifen treatment and hypoxia  
4-OHT was dissolved in ethanol to obtain a 1 mM stock solution and stored in light protected 
tubes at -20°C. For in vitro induction experiments 1 µM 4-OHT was added to cultured 
fibroblasts and incubated for 72 h followed by 24 h without 4-OHT. Cells were additionally 




cultivated under hypoxic conditions at 1% O2 (INVIVO O2, IUL Instruments GmbH, 
Königswinter, Germany and Gas Mixer Q, Ruskinn Technology Ltd, Bridgend, UK). 
 
gDNA isolation and polymerase chain reaction  
The gDNA was isolated from murine tissue samples and primary fibroblasts by alkaline lysis 
in 0.2 mM EDTA 25 mM NaOH for 1 h at 95°C. After cooling for 10 min at 4°C the solution 
was neutralized with 40 mM Tris pH 5.0. The dissolved gDNA was used for polymerase 
chain reactions (PCR) to either determine the mouse genotype or for evaluation of the PHD2 
knock out efficacy after activation of the Cre-recombinase. By utilizing PCR the specific 
DNA regions are amplified in a three step process. In the first step the genomic double 
stranded DNA is denaturized, the second involves annealing of specific primers to the 
sequence of interest followed by subsequent elongation performed by a thermo stable DNA 
polymerase. The annealing temperature depends on the base composition and length of the 
used primers. Primers used for genotyping and PHD2 knock out analysis are listed in Table 1. 
Table 1: Primers used for genotyping and PHD2 knock out analysis 
Primer name Sequence 
Annealing 
temperature 
Cre forward 5’-GTTCGC AAGAACCTGATGGACA-3’ 60°C 
Cre reverse 5’-CTAGAGCCTGTTTTGCACGTTC-3’ 60°C 
PHD2 intron 1 forward 5’-CTCACTGACCTACGCCGTGT-3 61°C 
PHD2 exon 2 reverse 5’-CGCATCTTCCATCTCCATTT-3’ 55°C 
PHD2 intron 3 reverse 5’-ACCACCCCGTCTGACAATTC-3’ 56°C 
PCR was performed in a total reaction volume of 25 μl containing 6.5 µl H2O, 5 µl DNA 
template, 0.5 µl forward primer (20 pmol/µl), 0.5 µl reverse primer (20 pmol/µl) and 12.5 µl 
2x PCR Mastermix (Thermo Fisher Scientific Inc.). The reaction was carried out in the Arktik 
Thermal Cycler (Thermo Fisher Scientific Inc.) with PCR cycling parameters as listed in 
Table 2. 
Table 2: PCR cycling parameters for mice genotyping and PHD2 knock out analysis 
Step 
Genotyping PCR for Cre 
PHD2 genotyping /knock out 
analysis 
Time Temperature  Cycles Time Temperature  Cycles 
Initial denaturation 4 min 94 °C  1 2 min 94 °C  1 
Denaturation 30 sec 94°C 
 30 
30 sec 94°C 
 30 / 35 Annealing 30 sec  60°C 30 sec 56°C 
Elongation 75 sec 72°C 7 min 72°C 
Final elongation 7 min 72°C   1 10 min 72°C   1 




Agarose gel electrophoresis 
Agarose gel electrophesis was used to separate and visualize DNA fragments of different 
sizes. Therefore agarose gels at concentrations of 1% or 2% were cast in 0.5x TBE buffer 
(44.5 mM Tris, 44.5 mM boric acid, 1 mM EDTA, pH 8.0) depending on the expected size of 
the amplified DNA fragments. To visualize the fragments Roti
®
-Safe GelStain (Carl Roth 
GmbH + Co. KG, Karlsruhe, Germany) was added to the liquid agarose gels according to the 
manufacturer’s instructions. To load the samples on the gel 6 µl OrangeG loading dye (30% 
glycerin and 0.25% Orange G in water) were added to the reactions. In addition 5 µl of either 
a 100 bp or 1 kb molecular weight markers (#SM0322 and #SM0311; Thermo Fisher 
Scientific Inc.) were used to determine the size of the separated DNA fragments. The agarose 
gel electrophesis was performed at 100 V for 1 h. The DNA was visualized with an UV-
transilluminator at 302 nm (Syngene, Cambridge, UK).  
 
mRNA isolation 
To analyse the PHD2 knock out efficacy on mRNA level the cultured primary fibroblasts 
were washed with chilled PBS and lysed using TRIzol
®
 Reagent (#15596018, Ambion, 
Carlsbad, USA). The suspension was scraped off the cell culture dish and incubated 5 min at 
RT. 0.2 ml chloroform were added per 1 ml TRIzol
®
 Reagent and vortexed. After incubation 
for 5 min at RT the samples were centrifuged at 12000 rpm for 15 min at 4°C to separate the 
RNA containing aqueous phase from the phenol-chloroform phase. 0.5 ml isopropanol per 
1 ml TRIzol
®
 Reagent were added to the upper aqueous phase. After incubation at RT for 
10 min the precipitated RNA was pelleted by centrifugation at 12000 rpm for 10 min at 4°C. 
The pellet was washed with 1 ml 75% ethanol, vortexed and centrifuged again at 7500 rpm 
for 5 min at 4°C. The pellet was air dried for 10 min and resuspended in 15 µl RNase-free 
water at 56°C for 10 min. The RNA concentration and purity was determined by measuring 
the absorption at 260 nm and the ratio 260 nm/280 nm using the SmartSpec
TM
 Plus 
photometer (Bio-Rad, Munich, Germany). 
 
cDNA synthesis 
Complementary DNA (cDNA) from mRNA templates was synthesised by using the First 
strand cDNA Synthesis Kit (# K1612; Thermo Fisher Scientific Inc.). It contains the M-
MuLV reverse transcriptase which catalysis the reaction as well as Oligo (dT)18 primers, 
which selectively bind to the 3’-end of poly(A) RNA ensuring synthesis of cDNA only from 




poly(A) tailed mRNA. 2 μg RNA were mixed with 1 μl oligo(dT)18 primer (0.5 μg/μl) and 
RNAse-free water up to a volume of 11 μl. The mixture was gently mixed and incubated at 
65°C for 5 min. The samples were chilled on ice and subsequently 4 μl 5x reaction buffer, 
1 μl RiboLock RNAse inhibitor (20 U/μl), 2 μl 10 mM dNTP and 2 μl M-MuLV reverse 
transcriptase (20 U/μl) were added to the reaction. cDNA synthesis was performed by 
incubation at 37°C for 60 min. The reaction was stopped by incubating the samples at 70°C 
for 10 min, which inactivates the M-MuLV reverse transcriptase.  
 
Quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) allows the quantification of starting amounts of 
cDNA templates. With every amplification cycle fluorescent reporter molecules are linked to 
the PCR products and the intensity can be detected relative to the amount of the amplified 
product. The 2x SensiMix
TM
 SYBR Low-ROX Kit (Bioline GmbH, Luckenwalde, Germany) 
was used in combination with a MX3000P light cycler (Stratagene/Agilent Technologies, 
Waldbronn, Germany). The fluorescent reporter molecule SYBR
®
 Green I binds double 
stranded DNA and the resulting fluorescence can be detected during the DNA amplification. 
ROX
TM
 dye (5-carboxy-X-rhodamine, succinymidyl ester) was used as reference dye. For the 
qRT-PCR 1 μl cDNA was added to 12.5 μl 2x SensiMix
TM
 SYBR Low-ROX mix, 0.5 μl 
forward primer (10 μM), 0.5 μl reverse primer (10 μM) and water to a total volume of 25 μl. 
To normalize for cDNA differences between samples, the ribosomal protein RNA mS12 was 
used as reference. Primers used are listed in Table 3 and the conditions used for the qRT-PCR 
are described in Table 4.  
Table 3: Primers used for the qRT-PCR anaylsis 
Primer name Sequence 
Annealing 
temperature 
mS12 forward 5’-GAAGCTGCCAAGGCCTTAGA-3’  60°C 
mS12 reverse  5’-AACTGCAACCAACCACCTTC-3’ 60°C 
mPHD2 exon 3 forward 5’-TTGCTGACATTGAACCCAAA-3 53°C 













Table 4: Steps and thermal cycling conditions used for the quantitative real-time PCR 
Step Time Temperature Cycles 
Initial denaturation 10 min 95 °C 1 
Three step PCR 
denaturation  30 sec 95 °C 
40 annealing 20 sec 60 °C 
elongation 30 sec 72 °C 
Amplification of the 
dissociation curve  
denaturation  1 min 95 °C 
1 annealing 30 sec 60 °C 
denaturation  30 sec 95 °C 
 
The Ct (threshold cycle) values, which are the number of cycles required for the fluorescent 
signal to cross the threshold, were analyzed using the MxPro program (MxPro-Mx3005P 
v4.10, Stratagene/ Agilent Technologies, Waldbronn, Germany). Statistical analysis of data 
was performed using GraphPad Prism 5.0 (GraphPad Software, Inc., San Diego, CA, USA). 
 
Protein extraction  
Cells were washed twice with cold PBS and lysed in fresh protein lysis buffer (400 mM NaCl, 
1 mM EDTA, 10 mM Tris/HCl, pH 8.0, 0.1% TritonX100) containing the protease inhibitor 
cocktail cOmplete Mini (Roche Applied Science, Mannheim, Germany). The suspension was 
removed from the plate with a cell scraper and incubated on ice for 10 min. The extract was 
centrifuged for 10 min at 4°C at 12000 rpm. The supernatant was transferred to a fresh tube 
and the protein concentration was determined by the Bradford protein assay reagent (Bio-Rad 
Laboratories GmbH, Munich, Germany). Per 1 µl protein sample 200 µl Bradford protein 
assay reagent was added. Additionally, a standard curve was created by using different bovine 
serum albumin (BSA) concentrations ranging from 0.5 μg to 6 μg to calculate the unknown 
concentrations of the samples. The protein concentrations were determined by measuring the 
absorption at 595 nm using a microplate reader (Model 680, Bio-Rad) and calculated via the 
Microplate Manager
®
 program (Microplate Manager
®
 V.5.2.1., Bio-Rad). 
 
SDS-PAGE and Immunoblot analysis 
Protein samples in Laemmli buffer containing sodium dodecyl sulphate (SDS) are denaturized 
and negatively charged and thus can be separated by size in an electric field using 
polyacrylamide gelelectrophoresis (PAGE). Reducing reagents like β-mercaptoethanol are 
additionally used to break down disulfide bonds and thus disrupt protein structure. SDS-
PAGE gels were used in concentrations of 10% for resolving gels and 5% for the stacking gel. 




First, the resolving gel was prepared and covered by isopropanol. After polymerization, the 
stacking gel was prepared and poured on top of the resolving gel after removing the 
isopropanol. The compositions of the used gels are listed in Table 5. 
Table 5: Composition of the resolving- and stacking gel 
 
Resolving gel (10%) Stacking gel (5%) 
H2O dest. 11.9 ml 6.8 ml 
30% Acrylamid/Bisacrylamid 10.0 ml 1.7 ml 
1.5 M Tris, pH 8.8 7.5 ml - 
1 M Tris, pH 6.8 - 1.25 ml 
10% SDS  0.3 ml 0.1 ml 
10% APS 0.3 ml 0.1 ml 
TEMED 0.012 ml 0.01 ml 
 
Differing amounts of protein (50-90 µg) were supplemented with 6x Laemmli buffer 
(100 mM Tris pH 6.8, 4% SDS, 0.2% bromophenol blue, 20% glycerol, 5% β-
mercaptoethanol). The samples were denaturized for 5 min at 95°C and loaded on the gel. 
Protein size was determined using the prestained PageRuler
TM
 (#26616; Thermo Fisher 
Scientific Inc.). The electrophoresis was performed at a constant current of 40 mA with 
maximum voltage set at 300 V using the PerfectBlue Doppelgelsystem Twin M (Peqlab, 
Erlangen, Germany).  
For further analysis, the proteins were transferred onto a nitrocellulose membrane 
(Amersham, Freiburg, Germany) using the semi-dry Western blot technique (PerfectBlue 
Semi-Dry Elektroblotter, Peqlab, Erlangen, Germany). The stacking gel was discarded 
beforehand. The nitrocellulose membrane, filter papers and resolving gel were soaked in 
transfer buffer (48 mM Tris, 39 mM glycine, 0.037% SDS, 20% methanol). The membrane 
and gel were sandwiched between the filter papers and the transfer was performed with a 
constant current setting of 2 mA/cm
2
 for 1 h. After protein transfer the membrane was stained 
in Ponceau S solution. Nonspecific binding sites were blocked with 5% milk in PBS for 2 h at 
RT. The detection of proteins was carried out by incubation with primary antibodies diluted in 
5% milk in PBS at 4°C overnight. The membrane was washed 3 x 10 min with PBS. 
Incubation with secondary HRP labelled antibodies diluted in 5% milk in PBS was performed 








Table 6: Used primary- and secondary antibodies 
Primary antibody Dilution Secondary antibody Dilution 
anti-HIF-1α (NB100-479; 
Novus, Littleton, USA) 
1:1000 
HRP-labelled anti-rabbit 




anti-PHD2 (NB100-2219; Novus, 
Littleton, USA) 




The membranes were washed three times with PBS and membranes were incubated with    
100 mM Tris-HCl, pH 8.5, 2.65 mM H2O2, 0.45 mM luminol, and 0.625 mM coumaric acid 
for 1 min. Chemiluminescence detection was performed using the LAS3000 system (Fuji) or 
by using chemiluminescence sensitive films (GE Healthcare, Munich, Germany).  
 
3.1.4 Results 
Strategy for generation of fibroblast-specific PHD2 knock out mice 
The generation of an inducible, fibroblast-specific PHD2 knock out mouse was performed by 
intercrossing Tg(Col1α2-cre/ERT) deleter mice with Phd2
flox/flox
 mice. The deleter mice 
express the inducible Cre-recombinase under the control of the Col1α2 promoter. A ‘far 
upstream enhancer’ region located 21.8 to –18.8 kb upstream of the start site of transcription 
of the the proα2(I)collagen gene restricts Cre-expression in fibroblasts but not in other type I 
collagen-producing cells (Bou-Gharios et al., 1996). Once activated by binding of 4-OHT, the 
Cre-recombinase permits recombination of the floxed Phd2 exon 2 and 3 which encode for 
the catalytic domain of the PHD2 enzyme (Figure 3A). This leads to a frameshift mutation 
resulting in a translational stop. For gDNA analysis primers were used which anneal upstream 
(Primer intron 1) and downstream (Primer intron 3) of the floxed Phd2 exons 2 and 3. The 
excision of exon 2 and 3 leads to a shorter gene sequence and thus a smaller PCR product.   
To activate the Cre-recombinase binding of 4-OHT to the mutated ERT is indispensable. 
Several TAM administration protocols were tested and evaluated for their PHD2 knock out 
efficacy on gDNA, mRNA, and protein level. Independent of the administration protocol 
genetic recombination could always be observed on gDNA level (Figure 3B). 
First 8-12 weeks old animals were fed with TAM containing chow for 7 weeks (Figure 3C). 
Secondly, intraperitoneal injections of TAM were performed with increasing dosages ranging 




from 40 mg/kg body weight, 80 mg/kg body weight, and 100 mg/kg body weight up to 
200 mg/kg body weight per day for 5 up to 10 consecutive days. Mice were studied at 
3 weeks and 8-12 weeks of age. In addition, one single injection of 1 mg TAM was performed 
in pregnant mice at day 12 PC. TAM is a prodrug which is metabolized mostly into its active 
4-OHT form predominantly by the cytochrome P450 (CYP) enzymes including CYP2D6 and 
CYP3A4 (Jordan et al., 1977). 4-OHT has an up to 100 times higher affinity than TAM and 
its other metabolites for binding to estrogen receptors and thus a greater potency to activate 
the Cre-recombinase (Malet et al., 1988). The 4-OHT exists as trans (Z) and cis (E) isomers. 
The Z-isomer is the more potent than the E-isomer (100x less) (Murphy et al., 1990). 
Therefore, one group of animals received 50 mg/kg body weight active 4-OHT per day 
consisting of either 70% Z-isomer or >98% Z-isomer. These mice were treated once weekly 
for three times starting at day 7 after birth or for 10 consecutive days of an age of 4 weeks.  
4 weeks after the last application or birth of offspring primary fibroblasts were isolated from 
heart, kidney, tail and skin and cultivated. Tail tip specimens were taken for PHD2 knock out 
analysis on gDNA level; mRNA and protein extracts were isolated from the cultured 
fibroblasts and the PHD2 knock out efficacy was determined. Besides the in vivo applications 
primary cells were also treated with 1 µM 4-OHT for 72 h in vitro and cultivated under 
normoxic (20% O2) or hypoxic (1% O2) conditions. 4-OHT undergoes a cis-trans (E-Z) 
interconversion process that occurs when incubated in cell culture medium (Malet et al., 
2002). Based on these data, a mixture of 70% Z-isomer and 30% E-isomer was used for in 
vitro studies.  




Figure 3: Generation of fibroblast-specific PHD2 knock out mice. A schematic drawing of the gene targeting 
strategy is shown. Exons 2 and 3 of the Phd2 locus are flanked by two LoxP-sites. Exons 2 and 3 are deleted by 
the activated Cre-recombinase which could be detected by using primers that anneal before and after the LoxP-
flanked region. B PCRs were performed to demonstrate deletion of floxed exons in Phd2 ko animals. C 
Treatment and analysis strategy for the induction of a fibroblast-specific PHD2 knock out are shown. Phd2 ko or 
Phd2 wt mice were treated with varying TAM administration protocols. In the first group animals were fed with 
TAM containing chow. In the second group i.p. injections of TAM were performed with increasing dosages and 
treatment periods. Additionally, single TAM injections i.p. were performed in pregnant mice at day 12 PC. The 
third group consists of animals which received either 70% Z- or >98% Z-4-OHT. 4 weeks after the last 
application or birth of the offspring primary fibroblast were isolated from heart, kidney, tail and skin and 
analyzed for PHD2 knock efficacy on mRNA- and protein levels. Besides the in vivo applications primary cells 









Tamoxifen has no effect on heart function 
As TAM may induce acute cardiomyopathy (Koitabashi et al., 2009) echocardiography of 
animals treated with TAM i.p. or vehicle oil was performed weekly before, during and after 
the administration of the drug. To exclude Cre-mediated effects animals either expressing the 
Cre-recombinase (Phd2 ko) or without Cre-recombinase (Phd2 wt) were examined. 
Additionally, the body weight was monitored to evaluate the physical condition of the animals 
during injection periods. Treatment with TAM had no impact on animal body weight (Figure 
4A) and no differences could be observed in FAS between the treatment groups (Figure 4B). 
Thus, it can be ruled out that TAM treatment leads to transient cardiomyopathy with the 
applied treatment protocols. 
Figure 4: Tamoxifen treatment does not affect body weight and heart function. A Body weight and B left 
ventricular fractional area shortening (FAS) of 3 weeks old mice were monitored before, during and after i.p. 
injections of 100 mg/kg TAM for 10 d. Data represent mean values ± SEM, n=3. No differences could be 
observed between TAM treated animals and the control group.  
 
The PHD2 knock out efficacy is not sufficient in Phd2 ko mice after TAM treatment 
Independent of administration route, dosage, treatment period and animal age, a sufficient 
knock out of PHD2 in heart fibroblasts could not be achieved. This was observed on mRNA 
level (Figure 5A) and protein level (Figure 5B). Fibroblasts were also isolated from the 
kidneys, tail and skin. In neither tissue fibroblasts a significant knock out of PHD2 could be 
detected in normoxia or hypoxia (Figure 5). In an approach to achieve the knock out of PHD2 
in the primary fibroblasts, cells were cultivated in the presence of 4-OHT. The PHD2 knock 
out efficacy remains unchanged by treatment of cells with 4-OHT in vitro and hypoxia 
(Figure 5B).  
 





Figure 5: PHD2 knock out efficacy is not sufficient after TAM treatment. A PHD2 mRNA analysis of 
fibroblasts isolated from heart, kidneys, tail and skin of mice after TAM treatment. B Protein analysis of primary 
fibroblasts from Phd2 wt (WT) or Phd2 ko (KO) mice which received i.p. 200 mg/kg body weight TAM. Cells 
were cultivated under normoxic (20% O2) or hypoxic (1% O2) conditions and treated additionally with 4-OHT in 
vitro. Immunoblot analysis for HIF-1α and PHD2; β-tubulin was used as loading control. 
 
3.1.5 Discussion 
Manipulation of the HIF pathway by interfering with PHD activity is an attractive strategy for 
cardiac tissue protection in myocardial ischemia (Katschinski, 2009; Hölscher et al., 2011; 
Vogler et al., 2015), Therefore, it is important to understand the effects not only in 
cardiomyocytes, but also in fibroblasts. However, the contribution of PHD2 and the HIF 
pathway to cardiac fibroblast function in the ischemic heart is not understood. To evaluate the 
role of PHD2 in cardiac fibroblasts, I focused on the generation of an inducible fibroblast-
specific PHD2 knock out mouse. Mice were generated by intercrossing Tg(Col1α2-cre/ERT) 
deleter mice which express an inducible Cre-recombinase under the control of the Col1α2 
promoter with Phd2
flox/flox
 mice. As several TAM administration protocols were described to 
activate the Cre-recombinase (Zheng et al., 2002; Hayashi and McMahon, 2002; Kiermayer et 
al., 2007; Denton et al., 2009), I evaluated their efficacy to generate a fibroblast-specific 
PHD2 knock out in this study. Genetic DNA recombination at the floxed PHD2 gene locus 
was observed with all TAM administration protocols; however hardly any PHD2 knock out 
was detected on mRNA and protein level. 
The Col1α2 promoter is mostly active during gestation with highest expression levels at E15.5 
during murine embryonic development and decreases after birth (Bou-Gharios et al., 1996; 
Florin et al., 2004). Therefore, TAM injections were additionally performed in pregnant mice 
during embryonic gestation at day 12 PC. However, the supposedly higher promoter activity 




and thus higher Cre-recombinase expression could not improve the PHD2 knock out efficacy 
on mRNA and protein level.  
TAM itself is a prodrug and metabolized mostly into its active 4-OHT form predominantly by 
the cytochrome P450 (CYP) enzymes including CYP2D6 (Jordan et al., 1977). 4-OHT has a 
higher affinity than TAM for binding to estrogen receptors and thus a greater potency to 
activate the Cre-recombinase (Malet et al., 1988). To address the question whether the used 
mice are poor metabolizer of TAM to 4-OHT due to a CYP2D6 variation (Gough et al., 
1990), mice were treated with active 4-OHT. As 4-OHT exists as trans (Z) and the 100x less 
potent cis (E) isomer (Murphy et al., 1990), animals received predominantly the Z-isomer. 
However, also injection with the active 4-OHT could not improve the knock out efficacy.  
Since the Col1α2 promoter may become reactivated concomitant with the transdifferentiation 
of fibroblasts into myofibroblasts upon cultivation of isolated primary fibroblasts (Santiago et 
al., 2010), additional treatment of isolated fibroblasts was performed with 4-OHT in vitro. 
Besides this, the Col1α2 gene can be induced by O2 deprivation (Distler et al., 2007). 
Therefore, cells were additionally cultivated not only under normoxic (20% O2), but also 
under hypoxic (1% O2) conditions. However, hardly any improvement of the PHD2 knock out 
efficacy on mRNA and protein level could be detected.  
Recently, Zimmermann et al., 2014 described the same inducible fibroblast-specific PHD2 
knock out mouse as used in this study, but without indicating details about their TAM 
administration routes. The authors observed reduced PHD2 mRNA and protein levels in skin 
fibroblasts. However, the reduction in PHD2 mRNA and protein as described by 
Zimmermann et al., 2014 could not be achieved in this study with neither TAM 
administration protocol. 
Without using cell type restricting enhancers, the Col1a2 promoter is expressed in all cells of 
the mesenchymal origin including fibroblasts, osteoblasts and chondrocytes (Florin et al., 
2004). This approach was used to investigate the function of PHD2 in skeletal development 
and the expression of PHD2 was successfully reduced in osteoblast lineage cells (Cheng et 
al., 2014). The authors do not analyze PHD2 expression levels in fibroblasts. Therefore it 
cannot be clarified whether these conditional PHD2 knock out mice would be suitable to 
analyze the function of PHD2 in cardiac fibroblasts.  
Because TAM was shown to induce transient cardiomyopathy (Koitabashi et al., 2009), heart 
function was analyzed after TAM treatment. However even at high TAM dosages no 
cardiomyopathy was observed. Thus TAM might have mouse strain-specific effects.  




In summary I could observe Cre-mediated genetic recombination of the Phd2 loxP sites via 
all TAM administration protocols, however hardly any PHD2 knock out could be detected on 
mRNA and protein level. This reveals an insufficient recombination activity which may be 
caused by an incomplete activation of the Cre-recombinase by TAM and 4-OHT or a low 
expression level of the Cre-recombinase.  
Thus, in future experiments a constitutive active fibroblast-restricted Cre-recombinase could 
be useful, however available mouse models which express the Cre-recombinase under the 
Col1α2 promoter (Cheng et al., 2014) as well as the FSP1 (fibroblast specific protein-1; 
S100A4) promoter (Bhowmick, et al., 2004) lack cardiac fibroblast-restricted expression 
patterns (Florin et al., 2004; Kong et al., 2013). Nonetheless, these mice could be of benefit 
for the analyses of fibroblastic properties after PHD2 knock out in the healthy and diseased 




























HIF is the transcriptional master regulator of the response of cells to oxygen deprivation. Up 
to now more than 200 HIF target genes are known that are involved in the cellular adaption to 
hypoxia (Semenza, 2002). PHDs play an important role in regulating the stability of HIFα. By 
inhibiting the PHDs the activation of the HIF signaling cascade can be achieved in normoxia. 
HIF signaling has been discussed to be an attractive strategy to protect ischemic tissue 
(Kastschinski, 2009) and HIF mediated protection has been shown in many tissues and organs 
including brain, kidney, lung, skeletal muscle, and the heart (Bernhardt et al., 2007).  
 
4.1 PHD inhibition as a therapeutic approach in ischemic heart disease  
Ischemic heart disease occurs when oxygen delivery is impaired and is not sufficient for the 
metabolic needs of the heart. This is e.g. the case in patients with a blockage of a coronary 
artery or in individuals with acute MI.  
In the 1990s it was shown that hypoxia prior to MI reduces the infarct size (Shizukuda et al.,  
1992, 1993). This finding could be linked to HIF-1α as hearts from heterozygous HIF-1α 
knock out mice, that were subjected to hypoxic preconditioning, were not protected against 
ischemia-reperfusion injury (Cai et al., 2003, 2008). In agreement with this, several genetic 
mouse models support the protective role of HIF in the heart (Kido et al., 2005, Hyvärinen et 
al., 2010; Moslehi et al., 2010; Hölscher et al., 2011). Elevated protein levels of HIF-1α are 
also found in the hearts of patients suffering from cardiomyopathy (Krishnan et al., 2009; 
Hölscher et al., 2012).  
As small molecular inhibitors of the PHDs can activate the HIF pathway in vitro and in vivo 
the effect of the pharmaceutical HIFα stabilization for ischemic cardioprotection has been 
much discussed and analyzed (Xi et al., 2004; Dendorfer et al., 2005; Eckle et al., 2008; Bao 
et al., 2010; Ong et al., 2014). The results of these studies underline the potential of small 
molecular inhibitors for cardioprotection but also revealed problems for clinical application. 
In the initial studies cobalt chloride and the iron chelator DFO were used to inhibit PHD 
activity (Xi et al., 2004; Dendorfer et al., 2005; Philipp et al., 2006). Also the effect of 
DMOG, a 2OG analogue, was exploited (Eckle et al., 2008; Zhao et al., 2010). Even though a 
cardioprotective outcome was shown for all of these substances, it is important to note that the 
substances are not PHD-specific and inhibit other Fe(II) containing enzymes and the enzyme 
family of 2OG-dependent-dioxygenases (which includes the PHDs), respectively. With 





improve cardiac function after myocardial infarction and ischemia reperfusion injury (Philipp 
et al., 2006; Bao et al., 2010; Ong et al., 2014). Besides selectivity of the PHD inhibitors 
another important parameter to be considered is the duration of treatment. The long-term 
treatment with GSK360A results in an increased hematocrit due to the induction of the HIF 
target gene EPO in the kidney and the liver (Bao et al., 2010). An increased hematocrit and 
subsequently higher blood viscosity leads to an increased afterload that could further harm 
infarcted and peri-infarcted cardiac tissue. Also studies using genetically modified mouse 
models indicate that a tight titration of HIF-1α levels is essential for preventing polycythemia 
and the preservation of cardiac function (Minamishima et al., 2008; Takeda et al., 2008; 
Minamishima et al., 2009; Bekeredjian et al., 2010; Hölscher et al., 2012). Indeed, the 
cardiac-specific dysregulation of HIF-1α levels is sufficient to induce dilated cardiomyopathy. 
Cardiomyocyte specific PHD2/3 double knock out mice show a very robust HIF-1α 
stabilization and develop a dilated cardiomyopathy already at young age (Minamishima et al., 
2009). In a cardiomyocyte-specific HIF-1α transgenic mouse model the development of 
cardiomyopathy was observed with progressing age of the mice (Hölscher et al., 2012).  
Thus, the data available to date show that manipulating the HIF system is principally well 
suited as a therapeutic approach to treat cardiac ischemia, however some risks occur. 
Especially long-term, excessive HIF activity is detrimental for cardiac function. Therefore it 
is important to induce a transient stabilization of HIFα to prompt the beneficial effects of the 
system whilst avoiding the risks. In this thesis the transient stabilization of HIF-1α  and HIF-
2α could be achieved using the selective PHD inhibitor ICA (Vogler et al., 2015, Figure 2). 
Two injections of ICA were shown to be sufficient to protect the heart in acute myocardial 
infarction. Although ICA was shown to induce the expression of EPO in a model of renal 
ischemia (Wang et al., 2012), it is important to note that the short term PHD inhibition that is 
described in this thesis did not affect the hematocrit (Vogler et al., 2015, Figure 4a-d).  
The cardioprotective effect of HIF has mostly been shown with interventions that precede 
ischemia (Abraham et al. (eds.), 2012). Post-conditional treatment however is a more 
practical approach for the therapeutic use in case of myocardial infarction or other ischemic 
diseases. In this thesis it could be shown that post-ischemic PHD inhibition with ICA exerts 
protective effects in acute myocardial infarction (Vogler et al., 2015, Figure 5d,e), indicating 
that there is a therapeutic time window to treat ischemic diseases. 
The mechanism of HIF-mediated tissue protection in ischemia is not understood so far and is, 
considering the diverse HIF target genes, presumably diverse. Changes in the cell metabolism 





remodeling could add to long term adaptive effects. Furthermore, the protective effect of 
HIFα stabilization cannot be linked to a specific cell. Many studies using genetically 
engineered mouse models show that PHD inhibition and HIFα stabilization in cardiomyocytes 
is beneficial in ischemic heart disease (Kido et al., 2005; Hyvärinen et al., 2010; Moslehi et 
al., 2010; Hölscher et al., 2011), however one study also describes the protective effect of 
PHD2 inhibition in cardiac endothelial cells (Kerkela et al., 2013).  
Cardiac tissue undergoes complex remodeling processes after myocardial infarction. These 
processes involve disruption of supporting structures, myocyte hypertrophy, inflammation, 
and collagen deposition both at the site of infarction and at areas remote from the infarct 
(Sutton and Sharpe, 2000). Cardiac fibroblasts are integral to the repair process. Hence, it is 
important to learn about the function of cardiac fibroblasts in hypoxia and after PHD 
inhibition and to gain knowledge about a putative influence of the HIF pathway on the cardiac 
remodeling process. Therefore, an inducible, fibroblast-specific PHD2 knock out mouse 
model would be useful to study fibroblastic properties especially in the diseased heart. 
However, a fibroblast-specific, TAM-inducible PHD2 knock out mouse could not be 
established in the present thesis. This might be due to the fact that the Cre-recombinase is, in 
order to achieve expression in fibroblasts, expressed under the control of the Col1α2 
promoter, which is most active just in early development. At later stages of development the 
promoter activity might not be sufficient to induce Cre-mediated recombination of the PHD2 
locus after TAM treatment. 
 
4.2 The role of hypoxia and HIF-1α in fibroblastic properties and actin dynamics 
As outlined above, in cardiovascular diseases (e.g. MI) fibroblasts play a central role in the 
myocardial remodeling process, which includes hypertrophy of cardiomyocytes (through 
paracrine interactions of fibroblasts and cardiomyocytes), migration and proliferation of 
fibroblasts and changes in the extent and composition of the cardiac extracellular matrix (Ieda 
et al., 2009;  Sun et al., 2000; Turner et al., 2003). However, little is known about the 
morphological and functional consequences of hypoxia on fibroblasts. In this thesis it was 
observed that L929 fibroblasts respond to oxygen deprivation with morphological 
modifications, including an increase in cell area and volume. Furthermore cell adhesion, cell 
spreading and motility were altered in hypoxia. This went along with profound changes of the 
actin cytoskeleton. In hypoxia F-actin containing stress-fibers were much more prominent 





1α, as HIF-1α knock down cells do not show increased F-actin formation in hypoxia. The 
remodeling of actin filaments in hypoxia with stress fiber formation has been observed in 
several cell types and might be a general phenomenon (Zieseniss, 2013). Enhanced actin 
polymerization and an increased assembly of F-actin rich parallel stress fibers were e.g. also 
shown in a human breast cancer cell line (MDA-MB-231) and were linked to HIF-1α induced 
RhoA expression (Gilkes et al., 2014). RhoA is a member of the Rho family of GTPases 
(Hall, 2012), which control actin dynamics by activating downstream signaling molecules. 
One downstream target of RhoA signaling is the ROCK/LIM-domain kinase/cofilin pathway 
(Olson and Nordheim, 2010). The actin-binding and severing protein cofilin is inactivated 
after phosphorylation by LIM kinase which causes F-actin polymerization. In line with the 
observation of Gilkes et al., 2014 that RhoA activity is increased in hypoxia in a HIF-
dependent manner, it was shown in this thesis that downstream of RhoA cofilin 
phosphorylation in hypoxia is HIF-1α dependent (Vogler et al., 2013, Figure 8). Furthermore 
in both studies a hypoxic increase of vinculin-containing focal adhesions is reported. In 
MDA-MB-231 cells focal adhesion formation is associated with increased cell motility in 
hypoxia (Gilkes et al., 2014). In L929 fibrosarcoma cells hypoxic cell spreading increases, 
however, cell velocity decreases in hypoxia (Vogler et al., 2013, Figure 2). As cytoskeletal 
dynamics are highly cell type dependent, it is not astonishing that despite the primarily similar 
observations of more stress fibers and focal adhesions in MDA-MB-231 and L929 cells, the 
migratory phenotype is different.  
Recapitulating, the findings in this thesis add to the emerging evidence that cytoskeletal 
properties are changed in hypoxia in several cell types and that the RhoGTPases play an 
important role in the hypoxic regulation of the actin cytoskeleton. This regulation might 
partially be HIF-dependent even though the mechanisms are not understood in detail so far. It 
is feasible to speculate that the actin arrangement of cardiac fibroblasts is also affected by an 










5. Summary and Outlook 
In this thesis the PHD enzyme inhibitor ICA was used to evaluate the effect of a 
pharmaceutical PHD inhibition in acute myocardial infarction. It could be shown that ICA 
exerts acute cardiac protective effects in myocardial ischemia resulting in a significantly 
reduced total infarct size. A treatment with the inhibitor done just twice was sufficient to 
induce a strong and rapid stabilization of HIF-1α and HIF-2α and their target genes. Notably, 
no increase in hematocrit was observed after two doses of ICA. Elevated hematocrit enhances 
the workload of the heart which is unfavorable in ischemic heart disease. Importantly, the 
cardio-protective effect of HIF pathway activation was not only observed in pre-conditional 
treatment but also after post-conditional application of ICA. This indicates that there is a 
therapeutic time window for the treatment with PHD inhibitors. 
When considering PHD inhibitors and the activation of the HIF pathway as a therapeutic 
approach to treat e.g. ischemic heart diseases, fibroblasts should be taken into account as they 
are pivotal for the myocardial remodeling. To understand the role of PHD2 and the effects of 
HIFα stabilization on fibroblastic properties, the generation of a fibroblast-specific PHD2 
knock out mouse, which expresses a TAM-inducible Cre-recombinase under the control of the 
fibroblast-specific, enhanced Col1α2 promoter, was attempted. Unfortunately, even though a 
Cre-mediated genetic DNA recombination of the Phd2 loxP sites was observed, hardly any 
PHD2 knock out was seen on mRNA and protein level. This could be due to an incomplete 
activation or inadequate expression level of the Cre-recombinase resulting in an insufficient 
recombination activity. An alternative approach to tackle the important question of the role of 
PHD inhibition and HIFα stabilization in fibroblasts in the setting of myocardial infarction 
could be the periostin (Postn)-Cre mouse model. In this transgenic mouse line the Cre-
recombinase is driven by a Postn promoter which is restricted to the non-myocyte lineage in 
the neonatal heart. The promoter is turned on after cardiac stress or disease onset. Using this 
mouse model it might be possible to generate a cardiac fibroblast-specific PHD2 knock out 
after myocardial infarction.  
In vitro data generated in this thesis further underscore the importance to analyze fibroblastic 
properties in hypoxia/ischemia. Using the L929 fibroblast cell line it could be shown that 
hypoxia greatly changes cell morphology and function including the reorganization of the 
actin cytoskeleton. The precise mechanism how actin dynamics are controlled in hypoxia is 
not known, however, evidence is compiling that RhoGTPase signaling is modulated in 
hypoxia. Evidence from this thesis suggests that changes in RhoGTPase activity in hypoxia 




are partially HIF-dependent. In the future it will be interesting to analyze if and how 
RhoGEFs and RhoGAPs are involved in hypoxic cytoskeletal dynamics.  
Overall this thesis helps to identify a pharmaceutical window in which the beneficial effects 
of the HIF response override potentially harmful side effects. Furthermore, I show that 
hypoxia has a profound impact on the regulation of the actin cytoskeleton of fibroblasts in 
vitro. Thus it is tempting to speculate that PHD inhibitors will also have an impact on 
cytoskeletal dynamics. Particularly with regard to the crucial role of fibroblasts in myocardial 
remodeling it is important to further understand the consequences of PHD inhibition on the 
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